Novo Nordisk A/S (NVO.N)
168.64USD
1:32am IST
$-0.28 (-0.17%)
$168.92
$168.52
$168.89
$167.15
31,519
45,188
$194.43
$129.44
NVO.N
About
Overall
| Beta: | 0.57 |
| Market Cap (Mil.): | $73,995.22 |
| Shares Outstanding (Mil.): | 442.51 |
| Dividend: | 3.18 |
| Yield (%): | 1.88 |
Financials
| NVO.N | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 25.04 | 34.14 | 34.28 |
| EPS (TTM): | 6.75 | -- | -- |
| ROI: | 48.74 | 19.49 | 18.85 |
| ROE: | 54.90 | 20.26 | 19.72 |
Novo obesity drug could launch in U.S. end 2014
COPENHAGEN - Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential.
UPDATE 1-Novo obesity drug could launch in U.S. end 2014
COPENHAGEN, May 24 - Danish drug maker Novo Nordisk said it could launch obesity treatment liraglutide in the United States by the end of next year and rejected some analysts' doubts over the medicine's commercial potential.
Novo sees US obesity drug launch end 2014/start of 2015-CSO
COPENHAGEN, May 24 - Denmark's Novo Nordisk said it expects to launch its liraglutide obesity treatment in the Unites States at the end of next year or start of 2015 after Phase III results late on Thursday confirmed weight loss in patients.
Novo Nordisk says obesity drug trial confirms weight loss
COPENHAGEN - Denmark's Novo Nordisk, the world's biggest insulin producer, said Phase III study results had shown people treated with its liraglutide drug had an 8 percent weight loss.
BRIEF-Novo Nordisk reports headline results for liraglutide trial
STOCKHOLM, May 23 - Novo Nordisk A/S : * Novo Nordisk A/S : Novo Nordisk reports 8% weight loss in phase 3a obesity
Novo Nordisk says completes hemophilia drug trial
COPENHAGEN - Denmark's Novo Nordisk, the world's biggest insulin producer, said on Friday it had completed the first phase III trial of a hemophilia drug, N9-GP.
UPDATE 3-NORDIC STOCKS - Factors to watch on May 17
(Adds Sanoma, Volvo, updates A.P. Moller-Maersk, FLSmidth)
Europe must pay up for new drugs: Novo Nordisk CEO
NEW YORK - Europe must start paying more for new medicines and take some of the cost burden of supporting pharmaceutical drug development off the United States, Novo Nordisk's Chief Executive Lars Sorensen said.
Novo's long-term targets hinge on two drugs: CEO
NEW YORK - Novo Nordisk's long-term profit targets are hanging in the balance after a big setback in the U.S. market but the Danish drugmaker may yet hit its goal if things work out for one of two drugs, its CEO said.
Sanofi says to step up development of new diabetes device
PARIS, May 2 - Sanofi is stepping up the development of a fixed combination of diabetes treatments Lantus and Lyxumia to sidestep an earlier setback with a similar pen device and take advantage of the delayed U.S. launch of competitor Novo Nordisk's new insulin.
Competitors
| Price | Change | |
|---|---|---|
| Eli Lilly & Co. (LLY.N) | $54.14 | -0.60 |
| Sanofi SA (SASY.PA) | €84.51 | -0.30 |
Earnings vs. 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
